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Introduction 
 
Somatotropin (GH) and insulin have opposite effects in glucose and lipids 
metabolism and synergic effects in the promotion of protein synthesis.  In a healthy 
individual, in the postprandial period, insulin is the most important anabolic 
hormone as it promotes glucose and lipids storage. During fasting, the action of GH 
predominates, switching the preferential energetic substrate through stimulation of 
lipolysis and sparing the stored proteins. Through this mechanism, GH increases  
plasmatic free fatty acids and ketone bodies concentration, promoting hepatic and 
peripheral insulin resistance (Table 1). 
Conclusion: 
Diabetic ketoacidosis is a very rare event in patients with acromegaly (1%). In our patients, its prevalence was 6,4% (N=47). In cases 1 and 2, initial GH 
secretion was very high and GH reduction led to a significant improvement in metabolic control.  In case 3, glycemic control worsened  probably due 
to the iatrogenic effect of prednisolone in a pancreas recently exposed to the glucolipotoxicity caused by GH. Somatotropin effects in carbohydrate 
metabolism and in the appearance of diabetic ketoacidosis in acromegaly are complex and not totally understood, but may be reversible with the 
reduction or normalization of GH levels.  
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Healthy individual Insulin GH IGF-1 Acromegaly 
Carbohydrates metabolism 
Glycemia ↓ ↑ ↓ N /↑ 
Glyconeogenesis ↓ ↑ ↓ ↑↑ 
Glycolysis  ↑ ↓ ↑ ↓ 
Insulin resistance ↑ ↓ ↑↑ 
Lipids metabolism 
Triglycerides synthesis  ↑  ↓ ↑ ↓↓ 
Lipolysis  ↓ ↑ ↓ ↑↑ 
Proteins metabolism 
Protein synthesis ↑ ↑ ↑ ↑ 
Proteolysis ↓ ↓ ↓ ↓ 
Acromegaly 
 
• Lipolysis and glyconeogenesis induced by GH may lead to decreased pancreatic insulin secretion, changes in the expression of the insulin gene and 
increased beta cell apoptosis.  
• If insulin production is not able to counterbalance the increased insulin resistance, glucose intolerance or diabetes may appear. Rarely, when there 
is a relative/absolut insulin deficit and an excess of counterregulatory hormones, diabetic ketoacidosis may occur.  
• The severity of glucose metabolism disturbance may be related to GH plasmatic concentrations (>25ng/ml).  
Case 1 
Male, 26 years 
Case 2 
Male, 27 years 
Case 3 
Male, 35 years 
Clinical presentation 
• Diabetic ketoacidosis as first manifestation of DM 
• No family history of DM 






No antidiabetic drugs in the first 2 months. 
Metformin 2g/day, Insulin 0,8U/Kg/day 
Transsphenoidal surgery  Partial remotion of the adenoma 
Total remotion of the adenoma (?)  
(January 2013) 
Histologia GH  difuse GH dense Necrosis 
Evolution DM treatment Suspension after 8 m Suspension after 7 M 
Metformin 3g/day, sitagliptin 100mg/day; insulin 
suspension after 3 months. 
Acromegaly treatment Octreotide LAR 30mg Octreotide LAR 20mg 
Initial clinical presentation: pituitary apoplexy 
and panhypopituitarism.  
Treatment: prednisolone, levothyroxine, 
testosterone. Future Radiosurgery Surgery 
Clinical cases (Table 2) 
Tabela 1 – Main metabolic effects of insulin, GH and IGF-1 
Table 2 –  Clinical cases 
Figure 5  – Evolution of HbA1c  Figure 4 – Evolution of  IGF1 Figure 3  – Evolution of GH 
Figure 2 – Clinical case 3: before surgery 
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